Amgen Inc.
AMGN · Nasdaq
AMGN · Nasdaq
Amgen is a global biotechnology company that discovers, develops, manufactures and sells human therapeutics. Its medicines address areas including oncology, inflammation and rare diseases, with IMDELLTRA and TEZSPIRE among the products highlighted in current evidence. The company earns revenue primarily from sales of its medicines; the supplied figures do not provide a segment revenue breakdown or quantify contributions by product or therapy area. Its customers include healthcare providers and patients, with medicines distributed through the healthcare system. Amgen reported FY2025 revenue of $36.8 billion and net income of $7.7 billion, compared with revenue of $33.4 billion and net income of $4.1 billion in FY2024.
Amgen gained 3.01% over the supplied reference window, rising from $447.28 to $460.73. After closing at $439.26 on October 23, shares recovered to $444.63 on October 26 and advanced on each subsequent session, finishing at $460.73 on October 29. Reports of positive Phase 3 results for Amgen’s TEZSPIRE in eosinophilic esophagitis and results showing IMDELLTRA with AstraZeneca’s IMFINZI reduced the risk of death by 58% in small-cell lung cancer provided favorable clinical context, though the evidence does not establish their direct effect on trading. Investors also approached Amgen’s upcoming Q3 report amid debate over drug-sales growth and biosimilar, pricing and cost pressures. On October 29, Amgen rose 1.97% despite a market slip.
Amgen gained 1.76%, rising from $417.57 on October 12 to $424.94 on October 19. The move was volatile: shares fell to $412.84 on October 13, then rallied sharply over the next two sessions to $434.03 on October 15, before easing to $432.49 on October 16 and falling again on October 19. Trading volume peaked during the October 15 advance at 4.63 million shares. The supplied evidence does not identify a company-specific catalyst for the interval; its headlines cover valuation, earnings and analyst targets but do not tie them to the trading days. No broader market performance or sector context is provided, so the available evidence does not establish what drove the rally and subsequent pullback.
Amgen rose $14.59, or 3.62%, over the reported span, from $402.98 on Oct. 5 to $417.57 on Oct. 12. Shares were nearly flat on Oct. 6 at $402.60, then jumped to $413.08 on Oct. 7, fell back to $407.44 on Oct. 8, and resumed gains to $414.87 on Oct. 9 before reaching the period’s highest close on Oct. 12. The rebound after Oct. 8 recovered the pullback and left shares above their prior close. The supplied evidence gives no dated company-specific catalyst for these moves, and it provides no market benchmark to attribute the gain to sector or broad-market performance.
AMGN fell 4.97%, from $423.64 to $402.60, with most of the decline concentrated on October 1 and 2: shares dropped to $407.27 and then $403.04. The stock was nearly flat in the next two sessions, closing at $402.98 on October 5 and $402.60 on October 6. The supplied evidence does not establish a company-specific catalyst for the sharp early-period selloff or provide market-index data to explain it as a sector or broader-market move. RBC Capital and Cantor Fitzgerald target increases, as well as a Morgan Stanley target reduction, appear in the evidence, but their dates are not supplied, so they cannot be tied to the week’s trading. The price series spans September 29 through October 6.
Amgen rose 0.30%, from $406.04 to $407.27 over the stated measurement period. The shares advanced from $414.61 on September 25 to $418.13 on Monday and a weekly high of $423.64 on Tuesday, then slipped to $421.51 Wednesday before dropping 3.38% Thursday, giving back nearly all of the gains. Zacks reported that the Thursday decline came while the broader market gained. The supplied evidence does not tie the trading moves to a dated company-specific announcement. A separate Motley Fool article mentions strong clinical-trial results for Amgen and Vertex candidates, but provides no date or candidate details linking those results to this week’s trading.
Amgen rose $29.74, or 7.90%, from $376.35 on September 16 to $406.09 on September 23. The main company-specific catalyst was positive Phase III news for dazodalibep: Amgen said the drug met its primary goal in systemic Sjögren’s disease, with sustained improvement through week 48, and coverage linked the result to the stock’s gain. Shares advanced to $393.16 on September 21 and then jumped to $410.24 on September 22, before giving back $4.15 on September 23. The supplied evidence does not identify a separate cause for that pullback. The move therefore reflects a strong response to the trial result, with a modest late-week reversal.
Amgen fell $36.71, or 8.54%, from $429.88 to $393.17 over the week, with the decline concentrated in the final session. The stock initially rose from $429.88 on August 31 to $444.12 on September 3, gaining as investors focused on positive oncology data, including a reported Phase 3 survival benefit for an Amgen-AstraZeneca combination in lung cancer. It then reversed modestly to $437.23 on September 4 before plunging to $393.17 on September 8 on heavy volume of 6.83 million shares. Coverage attributed the selloff to a trial setback involving a study Amgen did not run, alongside broader concern about the company’s oncology outlook. The move sharply underperformed the broader Nasdaq, which was supported by chip stocks.
Amgen rose 1.63% over the period, from $436.99 to $444.12, after initially weakening to $429.88 on Monday. The stock then reversed higher, gaining 1.9% Tuesday and continuing to advance through Thursday, when it closed at a new period high. The most concrete company-specific support was Wells Fargo’s decision to maintain its rating while raising its price target to $435 on the drug-trial outlook. Coverage also highlighted higher 2026 guidance, TEZSPIRE data and the potential of MariTide in obesity treatment. The move occurred without a material reversal after Tuesday’s rebound, although the stock first gave back the prior week’s losses before recovering them.
Amgen fell $6.91, or 1.57%, from $439.33 to $432.42 over the week. The stock initially gained $4.51 on Monday to $443.84, then declined on each of the next four sessions, including a $3.35 drop Thursday and a further $4.57 Friday. The most concrete company-specific development was Thursday’s announcement that AstraZeneca and Amgen’s Phase 3 CROSSING trial of Tezspire met its co-primary and key secondary endpoints in eosinophilic esophagitis, a positive result supporting potential expansion. That news did not prevent the late-week reversal, and the supplied evidence does not identify a specific reason for the subsequent selling. Articles also discussed Amgen’s exit from TScan’s Crohn’s deal and valuation, patent-loss and pricing risks.
AMGN rose 10.12%, from $378.87 to $417.20, extending gains on four of the five sessions shown. The stock climbed 2.9% on Aug. 4 and another 4.6% on Aug. 5, then gave back 0.7% on Aug. 6 before recovering 1.5% on Aug. 7 and 1.5% on Aug. 10. Trading volume peaked at 5.75 million shares on Aug. 5, materially above the surrounding sessions. The supplied evidence does not identify a definitive company-specific catalyst or broader-market explanation. Barclays maintained its rating while raising its price target to $380, and coverage highlighted strong GLP-1 demand, but neither item fully explains the move, particularly with the shares finishing above that target.
Amgen fell $3.08, or 0.78%, from $393.10 on July 28 to $390.02 on August 4. The stock dropped $5.46 on July 29, was unchanged July 30, and fell another $2.48 July 31 before reversing sharply with an $11.15 gain on August 4. The rebound followed second-quarter results showing improved profit and revenue growth, earnings and revenue beats of 12.32% and 6.52%, respectively, 37% growth in Repatha sales, and higher 2026 earnings guidance. Thus, the week reflected a material pre-earnings decline followed by a strong earnings-day recovery, but the rebound did not fully erase the earlier losses.
